INTERFERON-ALPHA-2B INSTILLATION PROPHYLAXIS IN SUPERFICIAL BLADDER-CANCER - A PROSPECTIVE, CONTROLLED 3-ARMED TRIAL

Sixty-seven patients with recurrent pT(a) G1-G3 to pT1 G1-G3 tumors were randomized into three groups receiving either Intron A at 10 MU/instillation, Intron A at 10 MU and mitomycin C (MMC) at 20 mg/instillation or MMC at 20 mg/instillation. After a mean follow up of 6.2 months no tumor recurrence has been seen in the group receiving combined therapy, whilst four out of 22 in the interferon group and five out of 23 in the MMC group suffered a recurrence. Side effects were slight. These preliminary results suggest that a combination of the two drugs is more effective than either drug alone.